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Caring for AML Patients During the
COVID-19 Crisis: An American and
Italian Experience
Lindsay Wilde1* , Alessandro Isidori2, Gina Keiffer1, Neil Palmisiano1 and
Margaret Kasner1
1 Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology,
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States, 2 Hematology and Stem Cell
Transplant Center, AORMN Hospital, Pesaro, Italy
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
the subsequent pandemic have impacted every aspect of oncology care worldwide.
Healthcare systems have been forced to rapidly change practices in order to maximize
the safety of patients and healthcare providers and preserve scare resources. Patients
with acute myeloid leukemia are at increased risk of complications from SARS-CoV-2
not only due to immune compromise related to the malignancy but also due to the acuity
of the disease and intensity of treatment. These issues have created unique challenges
during this difficult time. In this article, we present the approaches taken by two groups
of hematologist/oncologists, one in the United States and one in Italy, who have been
caring for acute myeloid leukemia (AML) patients in the face of the pandemic.
Keywords: acute myeloid leukemia, COVID-19, coronavirus, SARS-CoV2, pandemic
INTRODUCTION
The coronavirus-19 (COVID-19) pandemic is drastically altering care delivery across all oncologic
subspecialties. When safe and possible, delaying treatment is the logical approach in order to
decrease viral transmission, preserve scarce resources, and reduce the care burden on an already
stressed medical system. However, given the urgent presentation of acute myeloid leukemia (AML)
patients, and considering that cure is possible for some, watchful waiting is frequently impossible
or inadvisable. In this article, we compare the approach to treating patients with AML at the Sidney
Kimmel Cancer Center (SKCC) at Thomas Jefferson University in Philadelphia, PA, United States,
and at Marche Nord Hospital (MNH) in Pesaro, Italy, during the COVID-19 pandemic. We place
special emphasis on decision-making regarding identifying those patients for whom we can defer
treatment until a later, and hopefully safer, date and those for whom we cannot.
INITIAL DIAGNOSIS OF AML
The diagnosis of acute leukemia in the current era of molecular testing was a challenge even prior
to the COVID-19 pandemic. With the added strains of decreased access to in-person and inpatient
services, however, it is even more important to get a complete characterization of a patient’s
hematologic malignancy prior to starting therapy. It is also of the utmost importance to completely
characterize the leukemia and assess the need and potential for future stem cell transplant before
starting therapy, as the choice of treatment is being driven both by disease factors and by evidence
of and risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
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Prior to the current pandemic, two groups presented data
at the American Society of Hematology (ASH) 2019 Annual
Meeting demonstrating the safety of delaying the onset of therapy
until comprehensive molecular and cytogenetic characterization
of the disease is obtained. In the first study, the Alliance Leukemia
reported on more than 2200 patients presenting for aggressive
induction therapy and showed that overall survival did not differ
in patients of any age when assessed for days to treatment (0 to
greater than 15) (1). That being said, the majority (n = 1547)
of patients still started treatment between 0 and 5 days, while
447 began between 6 and 10 days, 106 between 11 and 15 days,
and only 163 beyond 15 days. Furthermore, the median time
from diagnosis to treatment was 3 days in the entire population,
confirming that only a minority of patients had a significant
treatment delay.
In the second study, the Beat AML Master Trial investigators
presented encouraging data in an older, more frail leukemia
population, demonstrating that patients who waited for 1 week
to enroll in a targeted therapy trial (when one was identified) had
superior outcomes to patients who opted to proceed more quickly
to standard of care (2). Of note, patients with hyperproliferative
disease or DIC were excluded from this study. Also, it is
important to remember that AML in the elderly population
has different biological characteristics, and a different treatment
algorithm, than in the younger population, which limits the
applicability of this study (3).
In the setting of COVID-19, and with the support of these
data, at SKCC every effort is made to perform a complete
diagnostic evaluation in the outpatient setting. This allows
patients to remain at home, isolated, for as long as possible
prior to starting therapy, thereby decreasing required visits
to the outpatient office and hospital and thus reducing both
patient and provider risk of exposure to SARS-CoV-2. Routine
monitoring of patients undergoing a diagnostic workup requires
frequent laboratory evaluations; however, the process has been
streamlined, and transfusion practices have been modified,
in order to maximize safety. A detailed discussion of our
recommended approach to supportive care will be presented in
a later section. In addition, telemedicine is utilized for symptom
screening, physician visits, and teleconsent for chemotherapy.
The approach at MNH, on the other hand, is to admit
patients to the hospital, where rates of SARS-CoV-2 transmission
are low, and keep them in isolation until diagnostic results
are available. Patient triage prior to admission is performed,
when possible, by telephone interview and includes questioning
on symptoms (fever, cough, rhinitis, and diarrhea) during the
15 days prior and exposure to COVID-19 positive contacts.
Patients with fever are managed in the emergency room, where
they perform triage, lab draws, and nasopharyngeal swab. Results
of the quantitative polymerase-chain-reaction on nasopharyngeal
swabs are available in 6–12 h. When the results are available,
patients are managed either outpatient at the hematology
department, if negative, or in one of the COVID-19 sub-intensive
or intensive care ward of the MNH Hospital.
Regardless of the logistical approach, we agree that
interpretation and application of the results of these trials
requires caution. Even if the data do support delaying
treatment to await the cytogenetic and molecular testing
for risk stratification and treatment planning, it is clear that this
strategy will not be appropriate for every patient, either during or
after the pandemic. For example, anyone with a life-threatening
complication such as tumor lysis syndrome, hyperleukocytosis,
or neutropenic sepsis should not have treatment delayed.
Furthermore, there are some data to suggest that delaying
treatment for younger patients may be of detriment. A previous
retrospective analysis showed a shorter survival for younger
patients (<60 years old) when treatment was delayed by ≥5 days
(4). In addition, since the younger population is treated primarily
with intensive daunorubicin (or idarubicin) and cytarabine (7+3)
induction, and since additional drugs, such as midostaurin or
gemtuzumab ozogamicin, are not added until after 7+3 has been
initiated, there may not be a benefit to waiting in these patients.
TESTING FOR COVID-19
Which patients to test for COVID-19 is not straightforward
and the guidelines at individual institutions and by national
organizations are evolving. Testing should be aimed at protecting
patients and the staff. To that end, we recommend universal
symptom screening at the front door of the clinic. Additionally,
we take the stance that any patient, provider, or staff member
could be an asymptomatic carrier and therefore employ universal
masking to reduce the risk of spread. In addition, we recommend
testing for all patients who are hospitalized or undergoing a
medical procedure, and any patient who will be receiving high
dose chemotherapy and/or stem cell transplant with the dual
goals of delaying therapy, when possible, and protecting staff if
therapy is required. Access to testing has been ramped up and is
now widely available at SKCC and MNH.
All patients with AML who are not hospitalized, regardless
of COVID-19 status, should isolate at home and perform all
interventions recommended by the World Health Organization
(WHO) to prevent transmission of SARS-CoV-2 outlined in
Table 1 (5).
UP-FRONT INTENSIVE AML THERAPY
Treatment of AML in unstable and/or potentially curable patients
should not be delayed, despite the increased risk posed by the
COVID-19 pandemic. Historically, the care of patients with AML
during the induction and peri-induction periods has required
prolonged hospitalization due initially to continuous infusion of
cytarabine and subsequently for monitoring and management of
complications of treatment. With the advent of newer therapies
and increased ability to deliver intensive supportive care outside
the hospital, this paradigm was changing, even prior to the
pandemic. In the present era, as minimizing the risk of SARS-
CoV-2 transmission is paramount, it is imperative that we
implement care models that minimize patient contact with each
other and with healthcare providers.
To this end, the SKCC has adopted the following care
processes aimed at (1) providing necessary and appropriate
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care for patients with AML and (2) managing patients outside
the hospital whenever possible. An induction strategy that
allows for outpatient treatment is preferred over a strategy
that requires hospital admission. We acknowledge that many
patients will still require hospital admission for complications of
induction therapy.
For patients for whom treatment with 7+3 is required, we
opt for early hospital discharge whenever possible. A number
of small, retrospective analyses have suggested the safety and
reduction in healthcare utilization of early discharge following
induction therapy with 7+3 (6–9). In these studies, no early
deaths (less than 30 days) were reported. The most frequent
adverse event was neutropenic fever, which often required
hospital re-admission. In one analysis, however, despite a median
of 1.5 hospital re-admissions per patient, the total number of
hospital days was still decreased by 30% when compared to
inpatient controls (6).
The largest prospective analysis to date on this approach
enrolled 178 adults with AML or high-risk MDS receiving
induction or re-induction therapy with 7+3 (10). Within 72 h
of completion of induction therapy, patients were assessed for
eligibility for early discharge based on a number of clinical
and logistical factors. One hundred and seven patients met
criteria and were discharged within 72 h of completion of
induction therapy. Twenty-nine patients were medically but not
logistically eligible for early discharge and served as inpatient
controls. Despite 93/107 (87%) early discharge patients requiring
readmission, primarily for neutropenic fever, they spent a median
of 8 days as inpatients (range 0–33) compared to a median of
16 days (range 3–42) for controls. Four early deaths occurred
(2.9%), all in the experimental arm, which was not statistically
significant (p = 0.58) and is comparable to the early death rate for
newly diagnosed AML.
For patients where treatment with liposomal
cytarabine/daunorubicin is indicated, outpatient induction
and consolidation is administered. Since the dosing regimen for
liposomal cytarabine/daunorubicin does not require continuous
infusion, it is possible to treat patients entirely in the outpatient
setting. The SKCC standard prior to COVID-19 was to see
TABLE 1 | World Health Organization (WHO) coronavirus disease (COVID-19)
advice for the public (5).
Recommendation Specific instruction
Wash hands frequently Use alcohol-based hand rub or
soap and water for at least 20 s
Maintain social distancing Maintain at least 3 feet (ideally 6
feet or more) from anyone
coughing or sneezing
Avoid touching eyes, nose, and mouth
Practice respiratory hygiene Cover mouth and nose with
bent elbow or tissue when
coughing or sneezing
Seek medical care early for fever, cough, and
difficulty breathing
Follow direction of local health
authorities
Stay informed and follow advice of healthcare
professionals
patients in the outpatient infusion center days 1–5 where they
receive liposomal cytarabine/daunorubicin via standard dosing
on days 1, 3, and 5. Laboratory studies and supportive care, such
as intravenous hydration and anti-emetics, are administered,
as needed, on days 1–5. This practice has been continued
during the pandemic. Patients who develop neutropenic
fever or other complications of induction are admitted to the
hospital, as needed.
The American Society of Hematology (ASH) has suggested
continuing to offer consolidative high-dose cytarabine (HiDAC)
to patients who achieve complete remission following induction
therapy (11). Specifically, it is proposed that the number of
HiDAC cycles be reduced to 3 from 4 and that the dose be
reduced to 1.5 g/m2 from 3 g/m2. The SKCC practice is to
continue to offer HiDAC consolidation with every effort made
to give this treatment at home via in-home infusion; this was
also our practice prior to COVID-19. With this treatment,
chemotherapy-trained nurses travel to the patient’s home once
per day on days 1–3 to infuse the first dose of the day and
set up the subsequent infusion each day. Laboratory studies,
toxicity assessments, and supportive care are also performed in
the patient’s home as indicated.
The approach to the intensive management of AML during the
pandemic at MNH has differed significantly from the approach at
the SKCC. First, all patients receive induction and consolidation
while in the hospital. Accordingly, there is the need to test all
patients’ nasopharyngeal swab and a quantitative polymerase-
chain-reaction test to detect SARS-CoV-2 infection (RNA) before
admission. Ideally, per European Hematology Association (EHA)
recommendations, all patients are then re-tested before each
treatment cycle, even if they have no symptoms (12). Once
hospitalized, all patients must observe a strict reduction of access
to visitors to decrease the possibility of becoming positive during
the hospital stay.
Symptomatic patients must wait for the results of the swab
before hospital admission. If positive, they are hospitalized in a
COVID-19 positive environment, with negative pressure when
possible. Any decision about treatment is delayed, and the clinical
situation is monitored strictly. Hydroxycarbamide is used to
manage COVID-19 positive patients as a bridge to intensive
therapy when needed.
Young, asymptomatic patients who are SARS-CoV-2 negative
receive standard induction mainly with 7+3. Consolidation with
cytarabine is also administered in the inpatient setting according
to the EHA recommendations; intermediate-dose cytarabine
with the 1/2/3 schedule is preferred, as several studies have
demonstrated comparable results with HiDAC (13).
Referral for hematopoietic stem cell transplant (HSCT) is a
challenging issue in the care of patients with AML under normal
circumstances. During the COVID-19 pandemic, issues such
as donor availability, testing, selection, and product availability
and recipient susceptibility to infection both pre- and post-
transplant have become particularly problematic. All transplant
registries have been negatively affected by COVID-19, with some
experiencing significant difficulty in collecting and exporting
products (14). However, delay of transplant, which may allow for
emergence of measurable residual disease, is known to negatively
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impact the survival of patients with AML (9). Therefore, despite
the risks and challenges, potentially curable patients with AML
at both SKCC and MNH continue to be referred for evaluation
for hematopoietic stem cell transplant as indicated. For patients
referred for HSCT who become infected with SARS-CoV-2,
the European Society for Blood and Marrow Transplantation
(EBMT) initially recommended deferral of transplant for at least
3 months; however, this guideline has evolved and the most
recent recommendation is to defer transplant for a minimum
14 days (ideally minimum of 21 days) and until the patient
becomes asymptomatic and has two negative PCR swabs at least
24 h apart (15).
NON-CURATIVE AML THERAPY
Perhaps the most difficult decision in the treatment of AML
during the COVID-19 pandemic is when to initiate therapy in
patients for whom cure is either unlikely or impossible with
today’s strategies.
In the older (specifically those age >75) and/or unfit
populations for whom transplant is unlikely to be considered,
careful discussions with patients and their families about
the risks of treatment are always paramount; however, these
discussions have become even more complicated in the COVID-
19 era. At the SKCC, and in the broader United States,
for the treatment of AML in the elderly/unfit population,
the anti-BCL-2 agent venetoclax in combination with a
hypomethylating agent (HMA) has clearly become the standard
of care. Initial phase 1 data demonstrated that this therapy
is safe and effective at inducing remission, with an overall
CR/CRi rate of almost 70%, although this varied significantly
by molecular subtype (16). Additionally in this study, the
large majority of patients with CRi obtained transfusion
independence of red cells (80%) and of platelets (93%)
with a median time to response of 1.2 months and best
response of 2.1 months. Recently presented abstract data
from the phase 3, randomized, double-blinded, multicenter,
placebo-controlled study of azacitidine plus venetoclax vs.
azacitidine plus placebo confirmed these results and showed
an overall survival of 14.7 months vs. 9.6 months, respectively
(HR: 0.66, 95% CI: 0.52–0.85, p < 0.001) (17). However,
in spite of its efficacy, this treatment regimen can have
significant side effects, namely profound and/or prolonged
neutropenia. This increased risk of infectious complications
must be weighed heavily when deciding to initiate treatment
in this vulnerable population. Overall, given the strength
of this combination to induce remission and, importantly,
to provide transfusion—and therefore outpatient infusion
clinic—independence, we consider the initiation of HMA and
venetoclax in older, unfit patients a priority even during the
current pandemic, especially for patients who are transfusion-
dependent at diagnosis.
As previously discussed, waiting for molecular sequencing
results prior to making a treatment decision is safe and feasible,
and oral targeted therapies are particularly attractive treatment
options in the wake of COVID-19. The genes for which an oral
targeted therapy currently exist include mutated FLT-3, IDH-
1, and IDH-2 and are present in approximately 50% of AML
patients (18). For upfront elderly/unfit patients with a targetable
mutation, an oral-only option is a preferred choice at this time,
with possible consideration for the potential addition of an HMA
in the future as more data emerge (16, 19–21).
Treatment of relapsed/refractory AML during the time of
the pandemic also requires difficult discussions with patients
and families as to goals of further therapy. If transplant, and
therefore potential for cure, is an option, as it would be in an
otherwise healthy younger patient, the choice at SKCC is to
pursue aggressive re-induction strategies, especially if on clinical
trial. However, if there is no potential for transplant, as always, it
is preferable to advocate for a lower-intensity, outpatient regimen
or palliative care.
The treatment approach for elderly, incurable, and/or relapsed
patients with AML at MNH, and throughout Europe, is starkly
different and was even before the pandemic. This is mainly
because, in the United States, venetoclax + HMAs, ivosidenib,
enasidenib, and FLT3 inhibitors are available in clinical practice,
but in Europe, they are not. Accordingly, treatment of elderly
patients outside of clinical trials and expanded access programs is
still very limited. Glasdegib + low dose cytarabine was approved
only very recently, and its use in clinical practice is now possible
(22). The hypomethylating agents, azacitidine and decitabine,
and low dose cytarabine are the only other available treatments.
The decision to initiate one of these treatments during the
pandemic is largely driven by SARS-CoV-2 status. If positive, it
is recommended that treatment be delayed until nasopharyngeal
swab RNA-negativity.
As always, for unfit or multiply refractory AML patients,
treatment on a clinical trial is preferred and enrollment has
continued both at SKCC and MNH during the pandemic. For
example, multiple oral-only therapies are under investigation at
the SKCC, including dihydroorotate dehydrogenase inhibitors
(DHODHi), Axl/Mer pathway inhibitors, among others. These
trials, which largely require in-person visits for PK/PD labs only,
can be incorporated into a relapsed/refractory patients’ existing
transfusion schedule, and therefore provide minimal increase in
exposure risk over supportive care alone.
TRANSFUSION AND GROWTH FACTOR
SUPPORT
Providing supportive blood and platelet transfusions is a
backbone of leukemia care. However, in the face of a potential
blood product shortage and during a time when exposure to
healthcare settings must be limited, modifications to institutional
transfusion practices have been necessary and implemented both
at SKCC and at MNH.
Few data exist regarding optimal red blood cell transfusion
thresholds in patients with AML, but data from trials in other
patient populations can be extrapolated and applied during
this time of need. For example, the TRICC and TRISS trials
previously established the safety of a restrictive hemoglobin goal
of 7 g/dL in critically ill patients (23, 24). Studies conducted
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in patients undergoing cardiac surgery and patients with upper
gastrointestinal bleeding demonstrated similar safety (24–29).
Perhaps most applicable, however, are the data from the more
recently published TRIST trial that randomized 300 patients
undergoing either autologous or allogeneic stem cell transplant
for a hematologic malignancy to a liberal (9 g/dL) or restrictive
(7 g/dL) threshold. The primary outcome of this non-inferiority
study was health related quality of life, measured by the validated
FACT-BMT score, and the results demonstrated non-inferiority
in the restrictive group at all time points (days 7, 14, 28, 60,
and 100). There were also no differences in secondary outcomes
including bleeding, mortality, infection, or platelet transfusion
(30). Taken together, these data support the decision to decrease
the red blood cell transfusion threshold from 8 g/dL to 7 g/dL
for those AML patients without significant cardiac disease or
anemia-related symptoms.
Relatively more data exist regarding platelet transfusion
thresholds in acute leukemia. The Platelet Trigger Transfusion
Trial was a multi-institutional study that randomized patients
with non-APL AML to prophylactic platelet transfusion with a
threshold of either 20,000 per cubic milliliter (liberal) or 10,000
per cubic milliliter (restrictive). With respect to the primary
outcome of major bleeding episodes, there was no difference
between the two arms (31). Other studies have replicated
these results (32–34). Thus, through patient and provider
reeducation, we have reinforced the safety of a prophylactic
platelet transfusion threshold of 10,000 per cubic milliliter
and adjusted our care model as needed to support this. For
those patients who require frequent platelet transfusions or
are transfusion refractory, we also consider the addition of
anti-fibrinolytics such as aminocaproic acid or tranexamic acid
(11, 35, 36).
Adjustments to protocols for administering growth factors
can also be effectively implemented to reduce or eliminate
the need for additional in-office visits. G-CSF can easily be
given at home via either an on-body injector or daily injection
and may reduce the risk of hospitalization due to neutropenic
fever or infection.
SUPPORTIVE CARE
The importance of continuing to provide comprehensive
psychological, social, financial, and emotional support for
leukemia patients during this time of increased stress cannot
be overstated. Transitioning programs that were previously
delivered face-to-face to virtual media platforms can be done
quickly and with relatively low expense. At the SKCC, multi-
disciplinary collaboration between social workers, palliative
and supportive medicine providers, financial counselors, and
physicians has allowed us to continue to offer psychological,
exercise, mindfulness, nutrition, survivorship, and support
groups to patients and their family members remotely.
Partnerships with local organizations have also served as a
means to connect patients to low or no cost WIFI resources,
provide technology support, and deliver groceries and other
essentials to patients in their homes.
Real-World Patient Experiences
Fortunately, only one patient with AML, an 82-year-old woman
receiving first line treatment with decitabine and venetoclax, has
tested positive for COVID-19 at the SKCC. She was treated with
supportive care in the hospital and ultimately discharged home;
she subsequently resumed outpatient chemotherapy. No patients
have delayed induction, consolidation, or transplantation, and
there have not been any confirmed COVID-19 related deaths in
our AML patient population.
At the MNH, between February 22 and April 26, 21 AML
patients were tested for SARS-CoV-2 before admission to the
ward. They all tested negative and proceeded with chemotherapy.
Furthermore, 3 patients with AML aged 39, 61, and 66 received
allogeneic stem cell transplantation (15). Several AML patients
with fever went to the ER and were tested for SARS-CoV-2.
Two patients aged 51 and 72 with relapsed AML waiting for
reinduction chemotherapy tested positive; they were admitted
to the intensive care unit and rapidly died due to interstitial
pneumonia. When lockdown ended, it became known that 3
other elderly AML patients cared for primarily at MNH had died
due to COVID-19 interstitial pneumonia in other hospitals in the
Marche region. All AML patients with active disease and SARS-
CoV-2 died due to interstitial pneumonia. No AML patient in
follow-up at our site had SARS-CoV-2 infection.
CONCLUSION
Caring for patients with AML during the COVID-19 pandemic
has presented unique challenges. However, through the rapid
development of a set of overarching principles to guide care,
changes in standard practices have been implemented in order
to protect patients and staff. At both the SKCC and MNH,
these principles have hinged on (1) continued provision of
standard AML treatment for patients who are curable or require
immediate intervention; (2) deferment of treatment for stable,
incurable patients; and (3) delivery of robust supportive care
services through innovative mechanisms. The SKCC approach
has also relied heavily on the utilization of outpatient care
(including telehealth and home visits) whenever possible, while
MNH has opted for an inpatient isolation protocol. We recognize
the need to revise and refine these practices as the COVID-
19 pandemic evolves, and as we plan for the post-pandemic
era of AML care.
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